Related Experiment Video

Updated: May 4, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

9.5K

Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer

Deborah Mukherji1, James Spicer

  • 1Guy's Hospital, King's College London, Division of Cancer Studies, 3rd Floor, Bermondsey Wing, Great Maze Pond, London SE1 9RT, UK.

Expert Opinion on Investigational Drugs
|February 27, 2009
PubMed

Insights

New EGFR inhibitors are being developed to treat advanced non-small cell lung cancer, aiming to overcome resistance to earlier drugs. These second-generation tyrosine kinase inhibitors utilize irreversible binding and multi-targeting strategies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are established treatments for advanced non-small cell lung cancer (NSCLC).
  • First-generation EGFR inhibitors like erlotinib and gefitinib are approved for second- and third-line therapy.
  • Resistance to first-generation EGFR inhibitors necessitates the development of more effective treatments.

Purpose of the Study:

  • To provide an overview of the early clinical development of second-generation EGFR tyrosine kinase inhibitors.
  • To highlight strategies employed in second-generation inhibitors to enhance efficacy and overcome resistance.
  • To focus on the application of these novel inhibitors in non-small cell lung cancer treatment.

Main Methods:

  • Review of early clinical trial data for selected second-generation EGFR tyrosine kinase inhibitors.
  • Analysis of drug development strategies, including irreversible binding and kinase multi-targeting.
  • Focus on preclinical and early-phase clinical investigations in NSCLC models and patients.

Main Results:

  • Second-generation EGFR inhibitors are designed to offer improved efficacy and overcome resistance mechanisms.
  • Irreversible binding and multi-targeting represent key strategies in the design of these novel agents.
  • Early clinical development is underway, showing promise for improved therapeutic outcomes in NSCLC.

Conclusions:

  • Second-generation EGFR tyrosine kinase inhibitors represent a significant advancement in NSCLC treatment.
  • These inhibitors aim to address limitations of first-generation drugs, particularly resistance.
  • Ongoing early clinical development is crucial for establishing the safety and efficacy of these next-generation therapies.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81